The authors reply.
Infectious Disease Division, The Alpert Medical School of Brown University, Providence, RI; Cooper Medical School of Rowan University, Camden, NJ; Department of Intensive Care, Erasme University Hospital, Brussels, Belgium; National Institutes of Health, Bethesda, MD; University of Pittsburgh School of Medicine, Pittsburgh, PA.
Steven M
SM
Opal
R Phillip
RP
Dellinger
Jean-Louis
JL
Vincent
Henry
H
Masur
Derek C
DC
Angus
D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D011486:Protein C / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D011486:Protein C